Fig. 5.
B7-H4 KO mice generate protective CD8 T cell immunity against 4T1-12B cells following gemcitabine treatment. B7-H4 KO mice that had previously eliminated or maintained stable tumor size (less than 3 mm in diameter) were re-challenged with 1 × 106 4T1-12B cells on the opposite mammary gland. a Tumor volume and b luciferase activity were measured every week post re-challenge. c Diagram depicting series of tumor inoculation and CD8 T cell depletion. Second injection more than 2 weeks after rejection of primary tumor; third injection more than 2 weeks after rejection of second tumor. d Final tumor volume of a representative CD8 T cell-depleted KO mouse re-challenged with 4T1-12B. Data presented as mean ± standard error. The presented data were either pooled from two to three experiments, or represent two or more independent experiments with similar results. *P < 0.05; **P < 0.01; ***P < 0.001